Pain with sex in midlife — dyspareunia — is usually attributed to low estrogen and thinning tissue, but that explanation is incomplete. A critical review found it is not highly correlated with menopausal status, estrogen levels, or vaginal atrophy. In a placebo-controlled trial, applying a topical anesthetic to the vestibule — the entrance, which is vulvar tissue, not vaginal — reduced penetrative pain by 88%, compared with 38% for placebo.

Key points

●      Pain with sex correlates poorly with estrogen levels or with how atrophic the tissue appears.

●      In 182 postmenopausal women with dyspareunia, the vestibule was the most common pain location.

●      In a randomized trial, numbing the vestibule reduced penetrative pain by 88% versus 38% for placebo.

●      The vestibule is androgen-responsive tissue, and anti-androgenic medications are an established cause of vestibular pain.

●      Pelvic floor tension can develop in response to pain and persist after the original cause is treated.

First — when to be seen

Some pain needs examination. See a clinician promptly for:

●      bleeding after sex, or any bleeding after menopause

●      a lump, sore, ulcer, or a patch of skin that has changed colour or texture

●      pain that is new, severe, or steadily worsening

●      pain on one side only

●      fever, or unusual discharge with an odour

Vulvar skin conditions and, rarely, vulvar cancer can present as pain with sex. Both are treatable, and both need to be looked at.

Isn't this just low estrogen?

That's the standard explanation, and the evidence behind it is weaker than most women are told.

A critical review of the research on postmenopausal dyspareunia set out to test the assumption that this pain is a direct symptom of hormonal decline. Its conclusion: dyspareunia is common after menopause but not highly correlated with menopausal status, estrogen levels, or vaginal atrophy. [1]

A later study by the same group tested this directly in 182 postmenopausal women with dyspareunia — measuring estrogen and progesterone by blood draw, assessing atrophy by gynecological examination and cytology, and measuring cognitive, emotional and relationship factors alongside them. [2]

Two findings came out of it. The traditional low-estrogen-and-atrophy model was not a sufficient explanation for the pain. And the vestibule — the entrance — was the most common location of postmenopausal pain with sex. [2]

This is not an argument that estrogen is irrelevant. It helps many women, and declining estrogen genuinely changes tissue. It's an argument that "your estrogen is low, your tissue is thin" is an incomplete account — and that incompleteness is why so many women improve partially, or not at all.

Where is the pain actually coming from?

For a substantial number of women, the vestibule rather than the vagina itself.

This has been tested directly. In a randomized, double-blind, placebo-controlled trial, 46 women with severe penetrative dyspareunia applied either 4% aqueous lidocaine or saline to the vulvar vestibule for three minutes before intercourse. [3]

The lidocaine group reported an 88% reduction in dyspareunia. The placebo group reported 38%. [3,4]

The implication is straightforward and easy to miss. If numbing a small patch of external tissue at the entrance largely prevents the pain, then the pain is arising there — not from thinning inside the vagina. The finding is cited in clinical consensus guidance. [4]

One thing to be clear about: the participants were breast cancer survivors, most estrogen-deficient because of their treatment. That's a specific group, not postmenopausal women in general. But it was a properly controlled trial, and the mechanism it demonstrates isn't specific to cancer treatment.

What is the vestibule, and why does it matter?

It's the area immediately at the vaginal opening — outside the vagina, part of the vulva. It's also the most common site of postmenopausal pain with sex. [2]

It develops from different embryonic tissue than the vagina does, and it behaves differently. It has its own nerve supply and its own patterns of inflammation. [5,6]

Treatment aimed at the vagina does not necessarily reach it. A woman using an internal vaginal product for pain located at the entrance may be treating a few centimeters from where it hurts.

How to recognise it: pain at the moment of contact or entry, rather than with deeper movement. Sometimes a finger, a tampon, or the pressure of a bicycle seat provokes it. Clinicians locate it with a cotton swab, testing points around the vestibule for tenderness. [7]

Why androgens matter here, not just estrogen

The vestibule is androgen-responsive tissue, and there is a recognised category of vestibular pain driven by androgen deficiency rather than estrogen deficiency.

Three separate lines of evidence point the same way.

Anti-androgenic medications cause it. Combined hormonal contraceptives are an increasingly recognised cause of vestibulodynia. [8] Spironolactone, an anti-androgen, has also been reported as a cause. [9] These lower available androgen — and vestibular pain follows.

The androgen receptor itself is implicated. Women who developed vestibulodynia while taking combined hormonal contraceptives were found to have significantly longer CAG repeats in the androgen receptor gene than women taking the same contraceptive who did not develop pain. [8] Longer repeats mean a less efficient receptor. The authors' interpretation: lowered free testosterone combined with an inefficient androgen receptor may predispose to vestibular pain.

And treatment reflects it. A study treating vestibulodynia with topical estradiol and testosterone together reported significant improvement in vestibular pain scores, alongside normalization of free testosterone. [10]

This matters because it reframes the problem. If the vestibule depends on androgen signaling as well as estrogen, then estrogen alone addresses part of the tissue's requirement — which is one explanation for why some women improve on vaginal estrogen and then stop improving.

→ Why Isn't Vaginal Estrogen Enough in Midlife? · How Vulvar Tissue Makes Its Own Hormones

These are prescription treatments requiring assessment. They are not something to self-direct, and they are not what a cosmetic moisturizer does.

Where exactly does it hurt?

This is the most useful question, and most women are never asked it.

Bring this distinction to an appointment. "Can we find exactly where it hurts?" is a more useful question than "is my tissue atrophic?"

Why does it still hurt after the cause was treated?

Because the pelvic floor can learn the pain and keep going.

When something hurts — an infection, tissue change, vestibular sensitivity — the pelvic floor muscles tighten in response. That's protective and normal.

But that tension can persist after the original cause has been treated, and become a maintaining factor in its own right. [1,5] The first problem resolves. The muscular response to it doesn't.

This is the mechanism behind an experience thousands of women have and almost nobody explains: I treated the dryness. It still hurts.

It doesn't mean the first treatment failed. It means a second thing started, and it usually needs pelvic floor physical therapy rather than more hormones.

Worth knowing: this hasn't been formally studied in postmenopausal women specifically. [1] The mechanism is well described in the pain literature; its role in midlife dyspareunia is inferred.

Does estrogen ever help?

Yes — and there's a nuance worth knowing if it hasn't worked for you yet.

A case series of women with severe postmenopausal genital pain found that prolonged estrogen therapy succeeded where standard courses had not. [11] That suggests the issue is sometimes duration and dose rather than estrogen being the wrong target altogether.

So "estrogen didn't work" may mean the wrong target, or it may mean not long enough. That's a conversation to have with your clinician rather than a reason to stop. Case series are weaker evidence than trials, and this is worth knowing about rather than acting on alone.

What else causes pain with sex in midlife?

More things than one article can diagnose, which is rather the point.

Alongside genitourinary syndrome of menopause and vestibulodynia: hypertonic pelvic floor, lichen sclerosus and other vulvar skin conditions, pelvic organ prolapse, scarring after surgery or hysterectomy, effects of cancer treatment including radiation, and vulvar cancer. [12]

Vestibulodynia is also associated with other chronic pain conditions — fibromyalgia, interstitial cystitis, irritable bowel syndrome — and with connective tissue disorders including hypermobility syndromes. [5] If you have any of those, mention it. It's relevant and rarely asked about.

Who should I see?

Often more than one person, and that isn't a failure of care.

Assessment may involve a medical clinician for examination and to rule out skin conditions and infection, a pelvic floor physical therapist for muscular assessment, and sometimes a sex therapist where pain has created anticipatory tension. [12]

Most women don't know pelvic floor physical therapy exists. If your pain is deep, or if it persisted after the original cause was treated, it's often the missing piece.

What if I've been told nothing is wrong?

A normal examination doesn't mean nothing is happening.

Vestibular pain isn't always visible. The tissue can look unremarkable while being exquisitely tender to light touch — which is why locating pain by touch matters more than looking at it. [7]

Two things worth saying in an appointment: ask to have the pain located, and say what's already been tried. That estrogen didn't resolve it is information, not failure — and it should prompt a different question rather than only a higher dose.

Dyspareunia in postmenopausal women remains substantially untreated, largely because women don't raise it and clinicians don't ask. [12] Only about a quarter of women with vulvovaginal discomfort seek help. [13]

It's a medical symptom, not a private failing.

Does anything topical help?

It depends entirely on where the pain is and what's driving it.

Lubricants reduce friction during sex and are worth using. They don't change tissue. → Why Vaginal Moisturizers Fail in Midlife

Vaginal estrogen helps many women, and may need longer than expected. → Why Isn't Vaginal Estrogen Enough in Midlife?

Restore Liposomal DHEA Vulvar Cream is a cosmetic vulvar moisturizer. It is not a treatment for pain, has not been studied for dyspareunia, and should not replace assessment. If sex hurts, the priority is finding out why.

A note on tissue

Most of the evidence in this article is based on vulvar tissue — the anesthetic trial, the androgen receptor findings, and the tissue histology all examined the vestibule directly. The exception is intracrine conversion: local production of active hormones from DHEA has been demonstrated in human vaginal tissue, and there is evidence that the same machinery is present in vulvar tissue, though it has not been characterized to the same level of evidentiary detail. 

Frequently asked questions

Is painful sex a normal part of menopause? Common, but not something to accept. It has identifiable causes, most treatable, and it correlates poorly with how menopausal you are. [1]

Why does it hurt at the opening rather than inside? The vestibule is distinct tissue with its own nerve supply and inflammatory patterns. [5,6] In 182 women, it was the most common location of postmenopausal pain with sex. [2] In a controlled trial, numbing it reduced penetrative pain by 88% versus 38% for placebo. [3]

Can estrogen and androgen both be used for vestibular pain? They are used together clinically. The vestibule is androgen-responsive, and anti-androgenic medications including combined hormonal contraceptives and spironolactone are established causes of vestibular pain. [8,9] One study treating vestibulodynia with topical estradiol and testosterone together reported significant improvement. [10] This is prescription treatment requiring assessment — not something to self-direct.

I'm using vaginal estrogen and it still hurts. What now? Worth asking to have the pain located precisely, asking about pelvic floor assessment, and asking whether a longer course is appropriate — prolonged therapy has helped where standard courses hadn't. [11]

Could this be something serious? Usually not, but vulvar skin conditions and rarely vulvar cancer can present this way. Bleeding, a lump, an ulcer, a colour change, or one-sided pain should be examined.

What is pelvic floor physical therapy? Assessment and treatment of the pelvic floor muscles by a specialist physiotherapist. A recognised part of dyspareunia care, and frequently the missing element. [12]

What's established, and what isn't

Established. Dyspareunia is common after menopause and not highly correlated with menopausal status, estrogen levels, or vaginal atrophy. [1] In 182 postmenopausal women with dyspareunia, the low-estrogen-and-atrophy model was not a sufficient explanation, and the vestibule was the most common pain location. [2] In a randomized, double-blind, placebo-controlled trial in 46 estrogen-deficient breast cancer survivors, topical anesthetic applied to the vulvar vestibule reduced dyspareunia by 88% versus 38% for saline placebo. [3,4] Combined hormonal contraceptives are a recognized cause of vestibulodynia, and affected women showed longer androgen receptor CAG repeats than unaffected women on the same contraceptive. [8] Dyspareunia has multiple recognised causes beyond GSM. [12]

Inferred. That locating pain by site is the most useful first step for a woman trying to understand her symptoms — this reflects clinical practice rather than a validated self-assessment method. That the vestibular findings extend beyond the breast-cancer population in which they were demonstrated — mechanistically reasonable, not directly shown.

Not established. The role of pelvic floor function in postmenopausal dyspareunia specifically hasn't been formally studied. [1] No topical cosmetic product has been shown to treat dyspareunia, including ours.

Educational note: This content is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any medical condition. Pain with sex should be evaluated by a qualified healthcare provider.

By Laura Kelly, DAOM, L.Ac., Dipl. O.M.  A California-licensed primary care provider and nationally board-certified clinician with a clinical focus on women’s health and healthy aging. Research Scholar, Ronin Institute. ORCID: 0000-0001-6586-7308.  More about Dr. Kelly

Published 8/2026 · Last reviewed 8/2026

References

1.   Kao A, Binik YM, Kapuscinski A, Khalifé S. Dyspareunia in postmenopausal women: a critical review. Pain Res Manag. 2008;13(3):243–254. doi:10.1155/2008/269571

2.   Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalifé S. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment. J Sex Med. 2012;9(8):2066–2076. doi:10.1111/j.1743-6109.2012.02771.x

3.   Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394–3400. doi:10.1200/JCO.2014.60.7366

4.   American College of Obstetricians and Gynecologists. Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer. Clinical Consensus No. 2. Obstet Gynecol. 2021;138(6):950–960.

5.   Pukall CF, Goldstein AT, Bergeron S, Foster D, Stein A, Kellogg-Spadt S, Bachmann G. Vulvodynia: definition, prevalence, impact, and pathophysiological factors. J Sex Med. 2016;13(3):291–304. doi:10.1016/j.jsxm.2015.12.021

6.   Leclair CM, Goetsch MF, Li H, Morgan TK. Histopathologic characteristics of menopausal vestibulodynia. Obstet Gynecol. 2013;122(4):787–793. doi:10.1097/AOG.0b013e3182a5f25f

7.   Goetsch MF, Lim JY, Caughey AB. Locating pain in breast cancer survivors experiencing dyspareunia: a randomized controlled trial. Obstet Gynecol. 2014;123(6):1231–1236. doi:10.1097/AOG.0000000000000283

8.   Goldstein AT, Belkin ZR, Krapf JM, Song W, Khera M, Jutrzonka SL, Kim NN, Burrows LJ, Goldstein I. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. J Sex Med. 2014;11(11):2764–2771. doi:10.1111/jsm.12668

9.   Mitchell L, Govind V, Barela K, Goldstein AT. Spironolactone may be a cause of hormonally associated vestibulodynia and female sexual arousal disorder. J Sex Med. 2019;16(9):1481–1483.

10.       Burrows LJ, Goldstein AT. The treatment of vestibulodynia with topical estradiol and testosterone. Sex Med. 2013;1(1):30–33. doi:10.1002/sm2.4

11.       Goetsch MF. Severe postmenopausal genital pain treated successfully with prolonged estrogen therapy: a case series and narrative review. J Low Genit Tract Dis. 2020;24(4):405–410. doi:10.1097/LGT.0000000000000553

12.       Streicher LF. Diagnosis, causes, and treatment of dyspareunia in postmenopausal women. Menopause. 2023;30(6):635–649. doi:10.1097/GME.0000000000002179

13.       Kingsberg SA, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Int J Womens Health. 2009;1:105–111.